NIH Awards The Texas Heart Institute $1.14 Million to Develop a Novel, First-in-Class Drug for Atherosclerotic Cardiovascular Disease (IMAGE)

Texas Heart Institute

NIH Awards The Texas Heart Institute $1.14 Million to Develop a Novel, First-in-Class Drug for Atherosclerotic Cardiovascular Disease

Caption

Dr. Darren G. Woodside (pictured), Vice President for Research, Senior Investigator, and Director of the Flow Cytometry and Imaging Core at The Texas Heart Institute (THI), will collaborate with scientists in THI’s Molecular Cardiology Research Laboratories on a new $1.14 million NIH-funded grant to develop a first-in-class drug for atherosclerotic cardiovascular disease.

Credit

© THE TEXAS HEART INSTITUTE 2023

Usage Restrictions

Photo Credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.